Our recent webinar, held on May 23, 2024, featured Dr. Michael Tranfaglia, Medical Director and Co-Founder, and Katie Clapp, Co-Founder and President of FRAXA. This special event was divided into two focused sessions, each tailored to bring the latest advancements directly to you—whether you're deeply embedded in the scientific community, a healthcare professional, or a family affected by Fragile X.
FRAXA Research Grants & Scientific Insights
In the first session, Dr. Tranfaglia discusses the newest research grants awarded by FRAXA and shares critical insights from the latest scientific meetings. This part of the webinar highlights the innovative research being funded and the collaborative efforts driving us closer to understanding and treating Fragile X syndrome.
Highlights:
- Insights from the latest Fragile X scientific meeting
- Announcement of new Fragile X research grants
- Engaging Q&A with Dr. Michael Tranfaglia and Katie Clapp
Clinical Trials and Research Updates
The second session delves into the ongoing clinical trials, including significant updates on the Harmony Biosciences (Zynerba) Phase 3 Clinical Trial (RECONNECT) and the Tetra Therapeutics Phase 3 Clinical Trial of Zatolmilast. Listen in as our experts discuss these pivotal studies and their potential to become treatments for Fragile X syndrome.
Highlights:
- In-depth updates on the RECONNECT trial by Harmony Biosciences
- Insights into the Phase 3 clinical trial of Zatolmilast by Tetra Therapeutics
- Interactive Q&A session addressing community questions
